Pharmaceuticals: Healthcare reform in the US, positive for Indian Pharma
- US Supreme Court upheld healthcare reform: The US Supreme Court recently passed the landmark ruling, dubbed ‘Obamacare’, thereby upholding the controversial massive reform of healthcare coverage initiated by the President Barack Obama. Obamacare or Patient Protection and Affordable Care Act (PPACA) requires most Americans to have health insurance and is effective from 2014. This legislation could, however, get derailed if Mr. Obama is not re‐elected or the Republican Party opposes it. The Supreme Court ruled that the most debated part, requiring all US citizens to buy health insurance or pay a penalty, was "constitutionally valid" as the Obama administration justified the penalty as a tax. It also ruled that the government has the power "lay and collect taxes."
- Impact of reform on global pharma industry: For global pharma companies, increased demand of drugs due to greater number of insured consumers will largely offset higher fees and rebates associated with healthcare reform. Though costs related to healthcare reform will be upfront, the increased demand is unlikely to begin until 2014 (when the mandate goes into effect). The Healthcare Reform Law imposes an annual fee on any “covered entity engaged in the business of manufacturing or importing branded prescription drugs” beginning in 2011. Branded prescription drugs and biologics covered include: (i) Any prescription drug approved under section 505(b) of the FDA; and (ii) any biological product for which an application was submitted under section 351(a) of the Public Health Service Act. Sales of generic drug products will not affect calculation of annual fees.
- Positive impact on Indian generic companies: While this development is great news for American insurance (as it will add 26mn new policies to health insurance), pharmaceutical and hospital companies, Indian pharmaceutical companies too will benefit. Nearly 75‐80% of all prescribed drugs sold in the US are generic drugs, an area where Indian companies are strong. To keep the cost of medical treatment low, insurance companies will prefer to use the generics route.
Moreover, Section 10609 of the Healthcare Reform Law is intended to increase access to lower‐cost generic drugs by preventing innovators from delaying approval of generic products by making label changes to the brand name or listed drug. Prior to the Law, the labeling of a generic drug was required to match the labeling of the referenced brand name or listed drug, or it wasn’t approved. This provision will enable faster approvals of generic drugs.
- Interchangeable clause to pave biosimilar pathway in US: Biologics Price Competition and Innovation Act (BPCIA) authorizes FDA to create a new regulatory pathway for biosimilar biological products. This section recognises an abbreviated approval pathway for biological products that can be shown to be “biosimilar” to or “interchangeable” with an existing FDA‐licensed biological product. Innovator manufacturers of reference biological products are granted 12 years of exclusive use before biosimilars can be approved for marketing in the US. This sub section will allow Indian biosimilars to enjoy the same status as small molecule generics of off‐patent drugs made by pharma companies in India. Edelweiss highlights that companies like Dr. Reddy’s and Biocon have made good progress in biosimilar programs, while Cadila and Lupin are also scaling up.
Click here to read the full report
Have a question?
- Pharmaceuticals Sector: Identifying companies that offer sustainable opportunities
- Pharmaceutical sector: 18% YoY revenue growth
- Q2FY14 Preview: Pharmaceutical Sector
- Pharma Q2FY14 preview: Robust performance is likely to continue
- Pharma: Concerns on string of recent US FDA actions unwarranted
Also On IndiaNotes.Com
20 tips to come out of liquidity crisis
It's all about psychology
State Bank of India: Net profit down 35.08% to Rs23750.10 mn
AIA Engineering: Buy at CMP & add on declines
Weekly Technical: Add long positions in Nifty futures for the revised target of 6550
Sensex and Nifty settle above the crucial 21,000 and 6,250 levels respectively